218 related articles for article (PubMed ID: 23443810)
21. Novel lncRNA Erbb4-IR Promotes Diabetic Kidney Injury in
Sun SF; Tang PMK; Feng M; Xiao J; Huang XR; Li P; Ma RCW; Lan HY
Diabetes; 2018 Apr; 67(4):731-744. PubMed ID: 29222368
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy.
Hou X; Tian J; Geng J; Li X; Tang X; Zhang J; Bai X
Oncotarget; 2016 Jul; 7(30):47760-47776. PubMed ID: 27351287
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
Kölling M; Kaucsar T; Schauerte C; Hübner A; Dettling A; Park JK; Busch M; Wulff X; Meier M; Scherf K; Bukosza N; Szénási G; Godó M; Sharma A; Heuser M; Hamar P; Bang C; Haller H; Thum T; Lorenzen JM
Mol Ther; 2017 Jan; 25(1):165-180. PubMed ID: 28129112
[TBL] [Abstract][Full Text] [Related]
24. C66 ameliorates diabetic nephropathy in mice by both upregulating NRF2 function via increase in miR-200a and inhibiting miR-21.
Wu H; Kong L; Tan Y; Epstein PN; Zeng J; Gu J; Liang G; Kong M; Chen X; Miao L; Cai L
Diabetologia; 2016 Jul; 59(7):1558-1568. PubMed ID: 27115417
[TBL] [Abstract][Full Text] [Related]
25. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice.
Takamiya Y; Fukami K; Yamagishi S; Kaida Y; Nakayama Y; Obara N; Iwatani R; Ando R; Koike K; Matsui T; Nishino Y; Ueda S; Cooper ME; Okuda S
Nephrol Dial Transplant; 2013 Jan; 28(1):55-62. PubMed ID: 23028104
[TBL] [Abstract][Full Text] [Related]
26. Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21.
Zhang L; He S; Yang F; Yu H; Xie W; Dai Q; Zhang D; Liu X; Zhou S; Zhang K
Can J Physiol Pharmacol; 2016 Dec; 94(12):1249-1256. PubMed ID: 27704873
[TBL] [Abstract][Full Text] [Related]
27. Delivery of megsin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by down-regulating p27(kip1) level.
Liu M; Zhang Y; Chi Y; Zhai S; Wang B; Shi Y; Li Y
J Nephrol; 2012; 25(3):418-25. PubMed ID: 21928229
[TBL] [Abstract][Full Text] [Related]
28. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
Hamada Y; Fukagawa M
Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
[TBL] [Abstract][Full Text] [Related]
29. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
30. Renal expression of proto-oncogene Ets-1 on matrix remodeling in experimental diabetic nephropathy.
Liu DX; Liu XM; Su Y; Zhang XJ
Acta Histochem; 2011 Sep; 113(5):527-33. PubMed ID: 20598359
[TBL] [Abstract][Full Text] [Related]
31. circRNA_010383 Acts as a Sponge for miR-135a, and Its Downregulated Expression Contributes to Renal Fibrosis in Diabetic Nephropathy.
Peng F; Gong W; Li S; Yin B; Zhao C; Liu W; Chen X; Luo C; Huang Q; Chen T; Sun L; Fang S; Zhou W; Li Z; Long H
Diabetes; 2021 Feb; 70(2):603-615. PubMed ID: 33472945
[TBL] [Abstract][Full Text] [Related]
32. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
33. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Lassila M; Seah KK; Allen TJ; Thallas V; Thomas MC; Candido R; Burns WC; Forbes JM; Calkin AC; Cooper ME; Jandeleit-Dahm KA
J Am Soc Nephrol; 2004 Aug; 15(8):2125-38. PubMed ID: 15284298
[TBL] [Abstract][Full Text] [Related]
34. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice.
Wang X; Gao Y; Tian N; Zou D; Shi Y; Zhang N
Drug Des Devel Ther; 2018; 12():2431-2442. PubMed ID: 30122901
[TBL] [Abstract][Full Text] [Related]
35. [Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in IgA nephropathy].
Wang J; Chen X; Shi S; Zhang Y; Tian Y
Zhonghua Nei Ke Za Zhi; 2002 Feb; 41(2):75-8. PubMed ID: 11940298
[TBL] [Abstract][Full Text] [Related]
36. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1.
Liu F; Zhang ZP; Xin GD; Guo LH; Jiang Q; Wang ZX
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4252-4260. PubMed ID: 30024615
[TBL] [Abstract][Full Text] [Related]
37. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
38. The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio.
Ma X; Lu C; Lv C; Wu C; Wang Q
J Diabetes Res; 2016; 2016():6789402. PubMed ID: 26881255
[TBL] [Abstract][Full Text] [Related]
39. Effect of catalpol on diabetic nephropathy in rats.
Dong Z; Chen CX
Phytomedicine; 2013 Aug; 20(11):1023-9. PubMed ID: 23746755
[TBL] [Abstract][Full Text] [Related]
40. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.
Zhong X; Chung AC; Chen HY; Dong Y; Meng XM; Li R; Yang W; Hou FF; Lan HY
Diabetologia; 2013 Mar; 56(3):663-74. PubMed ID: 23292313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
